Skip to main content
. 2021 Sep 9;326(16):1627–1629. doi: 10.1001/jama.2021.15286

Figure. Prevalence of Aducanumab Trial Exclusion Criteria Among Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment.

Figure.

ADRDs indicates Alzheimer disease and related disorders; AD, Alzheimer disease; and MCI, mild cognitive impairment.